Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.
This article was originally published by HCPLive®.
A Mendelian randomization analysis provided new insight into the effect of hypothyroidism on the risk of diabetes and its related microvascular complications.1
According to the analysis, an increase in hypothyroidism was associated with an increased risk of developing type 1 diabetes (T1D), T1D with renal complications, severe nonproliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR). No association between type 2 diabetes (T2D) and T2D with renal complications was observed in the analysis.
“This study provides new insights into the prevention and treatment of diabetes and its microvascular complications, suggesting that hypothyroidism is a risk factor for new-onset diabetes and antithyroid drugs can worsen diabetes mellitus and its microvascular complications,” wrote the investigative team, led by Liming Chen from the NHC Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital.
Diabetic microvascular complications are the most common complication of diabetes, including diabetic kidney disease and diabetic retinopathy. Hypothyroidism is a systemic hypometabolic syndrome, with the main causes ranging from an autoimmune impairment, thyroid destruction, iodine overdose, and the use of antithyroid medications.2 Several studies have identified an increased prevalence of diabetes and complications in patients with hypothyroidism, as well as the reverse.
Chen and colleagues noted the causal relationship between hypothyroidism and diabetes and its complications has not been established and requires further investigation. In their analysis, two-sample Mendelian randomization using genome-wide association study (GWAS) summary statistics from the UK Biobank and FinnGen consortium was performed to assess this potential causal association.
Investigators collected hypothyroidism genetic variants from the UK Biobank. The FinnGen consortium was used to gather variants for T1D, T2D, and T1D with renal complications, severe NPDR, and PDR. Multiple methods of Mendelian randomization analysis, including MR–Egger regression, weighted median, inverse variance weighted, simple mode, and weighted model, were used to examine the causal association between hypothyroidism and diabetes and its microvascular complications.
Investigators identified 10,894,596 single nucleotide polymorphisms (SNPs) associated with hypothyroidism in the UK Biobank. After applying inclusion criteria, 83 SNPs were used for Mendelian randomization analysis. According to inverse variance weighted estimate analysis, hypothyroidism was associated with T1D (β = 9.059926; SE = 1.762903; P = 2.76E-07) and T1D with renal complications (β = 10.18375; SE = 2.021879; P = 4.73E-07).
However, hypothyroidism showed no causal relationship with T2D (β = 0.05664379; SE = 0.3902611; P = .8845977) or T2D with renal complications (β = -1.842231; SE = 2.440639; P = 0.45269264). Meanwhile, hypothyroidism was positively associated with severe NPDR (β = 8.427943; SE = 2.142493; P = 8.36E-05), as well as PDR (β = 3.100939; SE = 0.74956; P = 3.52E-05).
Chen and colleagues indicated the study is limited by the greater frequency of subclinical hypothyroidism over overt disease and is often asymptomatic. As a result, undiagnosed and the genetic variants associated with hypothyroidism are poorly defined. The analysis only included cases with diagnosed hypothyroidism, meaning GWAS including subclinical disease should be included in future research.
“This will guide the clinical use of medications in patients with hyperthyroidism and suggest the importance of diabetes screening in patients with hypothyroidism,” investigators wrote.
References
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
October 30th 2024Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More